{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Cjc-1295",
    "short_name": "CJC-1295",
    "aliases": [
      "CJC-1295 DAC",
      "CJC-1295 (no DAC)",
      "GHRH analog"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Investigational peptide discussed as a GHRH analog affecting GH/IGF signaling. Not an FDA-approved therapeutic drug."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-17",
      "human_use_note": "CJC-1295 is not an approved therapeutic drug. Human evidence exists for GH/IGF changes in controlled settings, but long-term safety and outcome evidence for enhancement use is limited."
    },
    "structure": {
      "sequence_oneletter": "",
      "amino_acid_seq": "",
      "molecular_formula": "",
      "molecular_weight": null,
      "structure_image_url": ""
    },
    "risk": {
      "current_score": 7,
      "severity": "high",
      "likelihood": "possible",
      "evidence_grade": "human_interventional",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Manipulating GH/IGF axis has systemic downstream effects (glucose handling, edema, blood pressure, sleep). Human studies show endocrine effects; however, long-term outcomes and safety in non-medical enhancement contexts are uncertain. Adolescents are higher consequence risk due to developing endocrine setpoints.",
      "risk_score": 7
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "moderate",
          "evidence_grade": "human_interventional",
          "text": "CJC-1295 is a growth hormone releasing hormone (GHRH) analog discussed for increasing growth hormone and IGF-1 signaling. Controlled human research has reported endocrine changes, but long-term clinical outcomes and safety for enhancement use remain uncertain.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "varies",
          "unit": "study-dependent",
          "min": null,
          "max": null,
          "frequency": "varies",
          "duration": "varies",
          "population_group": "general",
          "notes": "Descriptive only. This app does not provide protocols. Not instructions.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "developmental_risk_block": [
        {
          "title": "Developmental / Adolescent risk",
          "population_group": "adolescent",
          "confidence": "moderate",
          "evidence_grade": "mechanistic_only",
          "text": "Because CJC-1295 targets GH/IGF signaling, adolescents and still-developing endocrine systems should treat uncertainty as a meaningful risk. Long-term setpoint changes are not well characterized.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "interaction_summary": []
    },
    "interactions": {
      "drug_classes": [],
      "supplement_classes": [],
      "peptides": []
    },
    "evidence": [
      {
        "id": "E1",
        "title": "CJC-1295 increases growth hormone and IGF-1 in healthy adults (human interventional study)",
        "source_type": "pubmed",
        "source_id": "16352683",
        "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/",
        "published_date": "2006-01-01",
        "evidence_grade": "human_interventional",
        "notes": "Interventional human research reporting GH/IGF-1 changes. Does not establish long-term enhancement outcomes or safety in non-medical use contexts.",
        "year": 2006
      }
    ],
    "changelog": [
      {
        "date": "2026-01-17",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for CJC-1295",
        "detail": "Added GHRH analog entry with human endocrine evidence and strong uncertainty framing; flagged developmental risk due to endocrine setpoint concerns.",
        "evidence_refs": [
          "E1"
        ]
      }
    ],
    "meta": {
      "appears_in_blends": [
        "cjc-ipamorelin"
      ]
    },
    "topics": {
      "primary": [
        "topic_muscle_recovery",
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "cjc-1295"
  },
  "canonical_name": "Cjc-1295"
}
